SCHEMBL26197643

SCHEMBL26197643

Cc1ccc(C(O)C(F)(F)F)c(Br)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
TRPA1 O75762 2/20 0.37
CHRM1 P11229 1/20 0.37
SLC6A2 P23975 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
PTPN1 P18031 1/20 0.36
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HSP90AA1 P07900 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
PDE2A O00408 2/20 0.32
MAPT P10636 2/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19828711 0.81 TP53 (0.40) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL18791373 0.79 PDE2A (0.43) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL7128529 0.79 TRPA1 (0.57) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL1343758 0.79 APLNR (0.36) PDE2APTGS2
SCHEMBL25160178 0.78 TRPA1 (0.37) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL610499 0.78 PDE2A (0.35) LMNAL3MBTL1PDE2AHTT
SCHEMBL30027153 0.78 PDE2A (0.35) LMNAL3MBTL1PDE2AHTT
SCHEMBL20494591 0.78 PDE2A (0.35) LMNAL3MBTL1PDE2AHTT
SCHEMBL14141979 0.77 TDP1 (0.35) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL20906137 0.76 PTGS2 (0.30) PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS LMNA 4065/4885TRPA1 4699/4885CHRM1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.